Portage Biotech Inc. (NASDAQ:PRTG – Get Free Report) shot up 0.3% during trading on Thursday . The company traded as high as $4.13 and last traded at $3.82. 6,466 shares traded hands during trading, a decline of 99% from the average session volume of 495,940 shares. The stock had previously closed at $3.81.
Portage Biotech Price Performance
The stock has a market capitalization of $3.15 million, a PE ratio of -0.07 and a beta of 1.45. The firm’s 50 day simple moving average is $5.07 and its 200 day simple moving average is $4.73.
Hedge Funds Weigh In On Portage Biotech
A hedge fund recently bought a new stake in Portage Biotech stock. Sanctuary Advisors LLC acquired a new position in Portage Biotech Inc. (NASDAQ:PRTG – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 297,728 shares of the company’s stock, valued at approximately $63,000. Sanctuary Advisors LLC owned 28.36% of Portage Biotech at the end of the most recent quarter. 13.36% of the stock is owned by hedge funds and other institutional investors.
About Portage Biotech
Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.
See Also
- Five stocks we like better than Portage Biotech
- Stock Sentiment Analysis: How it Works
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- What Makes a Stock a Good Dividend Stock?
- Texas Instruments: The Old-School Tech Titan Still Delivering
- What Are Some of the Best Large-Cap Stocks to Buy?
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
